XCancer

Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer

Description:

Medullary thyroid carcinoma (MTC) is a rare tumor arising from C cells of the thyroid gland and belonging to the endocrine tumors. 18F-DOPA PET, based on tha capacity of endocrine tumor cells to take-up, decarboxylate and store amino-acids, such 3-4-dihydroxyphenylalanine(DOPA), is used for imaging endocrine tumors. The aim of the study was to evaluate the contribution of 18F-DOPA whole-body PET for the detection of recurrences in patients with proven recurrent MTC without evidence of recurrence or metastases on several imaging modalities.

Sponsor:

Assistance Publique - Hôpitaux de Paris

Phase:

Phase 2

Contacts:

Badia-Ourkia HELAL, MD (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT00647140 - Click here to see study on

ClinicalTrials.gov

DOPA

Isotope(s):
Target(s):
  • Amino Acid Transport
Ligand Class: Small Molecules
Inclusion
  • Patients with medullary thyroid cancer / carcinoma recurrence, which have a high calcitonin level / rate, more than 100pg/ml, associated - or not - to a high CEA (Carcinoembryonic Antibodies) level / rate, dated from less than 3 months
  • Patients with a less than 3 months conventional imaging checkup (cervical ultrasonography, cervical-chest-abdomen tomography and / or magnetic resonance imaging, abdomen ultrasonography, osseous / bones radionuclide imaging), in which the tumor site not certainty located
  • Informed Consent Form signed and dated by patients
  • * Patients up to 18 years old with medullary thyroid cancer / carcinoma
  • Patients which are "SECURITE SOCIALE" affiliated
Exclusion
  • Women able to procreate, without efficient birth control
  • * Pregnant or suckling women
  • Patients already included in another Nuclear Medicine or Imaging research protocol using ionizing radiations; the efficient dose accumulation will not exceed 20 mSv.